Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

3,265 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. Peterson J, et al. Urology. 2008 Jan;71(1):17-22. doi: 10.1016/j.urology.2007.09.002. Urology. 2008. PMID: 18242357 Clinical Trial.
Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis.
Peterson J, Yektashenas B, Fisher AC. Peterson J, et al. Curr Med Res Opin. 2009 Mar;25(3):559-68. doi: 10.1185/03007990802694741. Curr Med Res Opin. 2009. PMID: 19196225 Clinical Trial.
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. Klausner HA, et al. Among authors: peterson j. Curr Med Res Opin. 2007 Nov;23(11):2637-45. doi: 10.1185/030079907x233340. Curr Med Res Opin. 2007. PMID: 17880755 Clinical Trial.
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Peterson J, et al. Clin Ther. 2007 Oct;29(10):2215-21. doi: 10.1016/j.clinthera.2007.10.008. Clin Ther. 2007. PMID: 18042477 Clinical Trial.
Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis.
Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB. Paglia M, et al. Among authors: peterson j. Curr Med Res Opin. 2010 Jun;26(6):1433-41. doi: 10.1185/03007991003795030. Curr Med Res Opin. 2010. PMID: 20394471 Clinical Trial.
Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program.
Morrow BJ, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. Morrow BJ, et al. Among authors: peterson j. Diagn Microbiol Infect Dis. 2013 Apr;75(4):412-6. doi: 10.1016/j.diagmicrobio.2012.12.012. Epub 2013 Feb 5. Diagn Microbiol Infect Dis. 2013. PMID: 23391609
Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.
Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. Queenan AM, et al. Among authors: peterson j. Diagn Microbiol Infect Dis. 2012 Jul;73(3):267-70. doi: 10.1016/j.diagmicrobio.2012.04.002. Epub 2012 May 12. Diagn Microbiol Infect Dis. 2012. PMID: 22579652
Levofloxacin versus azithromycin on the oropharyngeal carriage and selection of antibacterial- resistant streptococci in the microflora of healthy adults.
Nord CE, Peterson J, Ambruzs M, Fisher AC. Nord CE, et al. Among authors: peterson j. Curr Med Res Opin. 2009 Jun;25(6):1461-7. doi: 10.1185/03007990902953468. Curr Med Res Opin. 2009. PMID: 19419343 Clinical Trial.
Risk evaluation and mitigation strategies (REMS): educating the prescriber.
Nicholson SC, Peterson J, Yektashenas B. Nicholson SC, et al. Among authors: peterson j. Drug Saf. 2012 Feb 1;35(2):91-104. doi: 10.2165/11597840-000000000-00000. Drug Saf. 2012. PMID: 22171604 Review.
Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
Nicholson S, Peterson J, Yektashenas B. Nicholson S, et al. Among authors: peterson j. Expert Opin Drug Saf. 2012 Mar;11(2):299-314. doi: 10.1517/14740338.2012.650689. Epub 2012 Jan 10. Expert Opin Drug Saf. 2012. PMID: 22233294 Review.
3,265 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback